Basilea Pharmaceutica's Days Sales Outstanding for the
six
months ended in Dec. 2025 was 21.41.
Basilea Pharmaceutica's Days Inventory for the
six
months ended in Dec. 2025 was 267.12.
Basilea Pharmaceutica's Days Payable for the
six
months ended in Dec. 2025 was 151.04.
Therefore, Basilea Pharmaceutica's Cash Conversion Cycle (CCC) for the
six
months ended in Dec. 2025 was 137.49.
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Basilea Pharmaceutica Cash Conversion Cycle Related Terms
Basilea Pharmaceutica Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for Basilea Pharmaceutica's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:BSLN vs VRTX, REGN, ALNY: Cash Conversion Cycle Comparison
For the Biotechnology subindustry, Basilea Pharmaceutica's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Basilea Pharmaceutica Cash Conversion Cycle vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Basilea Pharmaceutica's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Basilea Pharmaceutica's Cash Conversion Cycle falls into.
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Basilea Pharmaceutica's Cash Conversion Cycle for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Basilea Pharmaceutica (XSWX:BSLN) has a Cash Conversion Cycle of 137.49 as of Dec. 2025. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Basilea Pharmaceutica and its competitors.
Is Basilea Pharmaceutica's Cash Conversion Cycle too high?
Basilea Pharmaceutica's current Cash Conversion Cycle is 137.49. The Biotechnology industry median Cash Conversion Cycle is 103.69. Basilea Pharmaceutica's value of 137.49 is 32.6% above this industry median. Overall, Basilea Pharmaceutica has a GF Score™ of 59/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Basilea Pharmaceutica's Cash Conversion Cycle compare to VRTX and REGN?
Basilea Pharmaceutica's Cash Conversion Cycle of 137.49 can be compared against companies in the Biotechnology industry. The industry median Cash Conversion Cycle is 103.69. Basilea Pharmaceutica's value of 137.49 is 32.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Biotechnology company?
The median Cash Conversion Cycle among Biotechnology companies is 103.69, based on 867 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Basilea Pharmaceutica's current Cash Conversion Cycle of 137.49 is 32.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Basilea Pharmaceutica and its competitors. For the Biotechnology industry, the median Cash Conversion Cycle is 103.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Basilea Pharmaceutica's current Cash Conversion Cycle is 137.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Basilea Pharmaceutica stock overvalued right now?
Based on GuruFocus' analysis, Basilea Pharmaceutica (XSWX:BSLN) is currently considered Fairly Valued. The stock's GF Value™ is CHF57.66, compared to a current price of CHF54.70 — trading 5.1% below its estimated fair value. The current Cash Conversion Cycle is 137.49 and 32.6% above the Biotechnology industry median of 103.69. Basilea Pharmaceutica's overall GF Score™ is 59/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Basilea Pharmaceutica (XSWX:BSLN), the current Cash Conversion Cycle is 137.49 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Basilea Pharmaceutica (XSWX:BSLN) Overvalued in 2026?
Based on GuruFocus' analysis, Basilea Pharmaceutica stock appears to be undervalued.
The current stock price of CHF54.70 is trading 5.1% below its estimated GF Value™ of CHF57.66.
GuruFocus considers Basilea Pharmaceutica to be Fairly Valued.
Key valuation signals for XSWX:BSLN:
Cash Conversion Cycle: 137.49
GF Value™: CHF57.66 vs. price of CHF54.70 (5.1% below fair value)
Industry Position: 32.6% above the Biotechnology median
No single metric tells the full story. See the XSWX:BSLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Basilea Pharmaceutica Ltd is a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing drugs to meet the needs of patients with severe bacterial and fungal infections. The Company has operating subsidiaries in the United Kingdom and Germany. Geographically company derives revenue from Japan, Ireland, Republic of Korea, USA, Uruguay, Sweden, Canada, Jordan, Switzerland and Other countries.
59GF Score
Get the complete analysis for XSWX:BSLN
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:BSLN has been successfully added to your 
